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ABSTRACT 
Objective: Neurocognitive (NC) performance among older persons, including those living with 
HIV (PLWH), exhibits significant heterogeneity, suggesting subpopulations with differing 
profiles of NC impairment (NCI). Metabolic factors are associated with NCI, but their 
relationships to profiles of NCI are unknown.  
Methods: Participants (144 PLWH, 102 HIV-uninfected) aged 50+ years completed a standard 
neuropsychological battery assessing seven cognitive domains. Latent class analysis (LCA) was 
used to identify NCI profiles, which were examined against the Montreal Cognitive Assessment 
(MoCA). Multinomial regression was used to identify metabolic factors associated with 
classification. 
Results: LCA identified three subgroups of NCI regardless of HIV status: Class1Multidomain NCI 
(high probability of impairment across multiple cognitive domains), Class 2Learning & Recall NCI 
(high probability of impairment in learning and recall), and Class 3NC Unimpaired (low probability of 
NCI across all domains). PLWH were more likely to be classified as Class1Multidomain NCI (p< 
0.05). Relative to those in Class 3NC Unimpaired, individuals in Class 1Multidomain NCI and Class 2Learning 
& Recall NCI had lower MoCA scores (ps< 0.05). Among PLWH, those with dyslipidemia, central 
obesity, or hypertension had greater odds of classification in Class 1Multidomain NCI than in Class 
3NC Unimpaired (ps< 0.05). Regardless of HIV status, those with diabetes were more likely to be in 
Class 1Multidomain NCI. 
Conclusions: Similar profiles of impairment among PLWH and HIV-uninfected individuals 
suggests common mechanistic pathways to NCI. Metabolic risk factors confer heightened risk of 
multidomain NCI in HIV infection. Interventions to reduce metabolic risk factors may improve 
NC outcomes among PLWH. 
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INTRODUCTION 
Despite the advent of combination antiretroviral therapy (cART), neurocognitive 
impairment (NCI) remains common among people living with HIV (PLWH). NCI among 
PLWH, also termed HIV-associated neurocognitive disorder (HAND), continues to be observed 
in up to half of PLWH in the cART era (1, 2). The neurocognitive profile of HAND reflects 
considerable interindividual variability, with a wide range of performance in terms of severity 
and patterns of domain-specific cognitive dysfunction (3). Although impairments in learning and 
executive functioning tend to be most prevalent in the cART era, many PLWH are also impaired 
in delayed recall, motor functioning, speed of information processing, and verbal fluency 
domains (2). Thus, NCI among PLWH exhibits significant heterogeneity, and this variability in 
cognitive performance suggests that subpopulations of PLWH may differ in risk factors and 
mechanisms contributing to NCI. 
NCI among PLWH may be mediated by a variety of neuropathological processes 
including chronic inflammation, incomplete HIV suppression in the central nervous system, 
neurotoxicity of antiretroviral drugs, and legacy effects following severe immunosuppression 
(i.e., nadir CD4 levels<200 ) (4-7). Additionally, with significant reductions in morbidity and 
mortality on cART, PLWH have improved longevity and are now experiencing age-related 
declines in cognition that are associated with neurodegenerative (such as Alzheimer’s and 
Parkinson’s) and cerebrovascular diseases (8-10).  
Multiple studies implicate metabolic syndrome (MetS), a constellation of related 
conditions (i.e., central obesity, hyperglycemia, dyslipidemia, and hypertension), with worse 
neurocognitive performance in PLWH, similar to the effects of MetS in the general population 
(10-13). However, older PLWH are at greater risk for developing metabolic conditions, 
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compared to age- and sex-matched controls (14-16). Thus, MetS may promote neuronal injury 
and could account for the higher risk of neurocognitive deficits among older PLWH (17). This 
notion of MetS-associated neurocognitive vulnerability among PLWH is supported by studies 
that have demonstrated that components of MetS heighten the risk for HAND and correlate with 
imaging markers of neurochemical abnormalities and neuroinflammation among older PLWH 
(11, 12, 18-20).  
Given variability in neurocognitive performance among PLWH and older adults, as well 
as individual differences in the presence of comorbidities that may impact neurocognitive 
performance, identifying neurocognitive profiles and their predictors is an important area of 
research. One approach that has been used to identify subgroups of individuals with similar 
patterns of neurocognitive performance is latent class analysis (LCA). LCA is an analytic 
method allowing the characterization of categorical unobserved (latent) variables from analyses 
of the structure of relationships among several observed variables. LCA has been utilized to 
uncover latent classes associated with Alzheimer’s and Parkinson’s diseases (21-23). Although 
metabolic factors have been associated with NCI among PLWH and HIV-uninfected individuals, 
the relationship of metabolic risk factors to profiles of NCI and their differential contributions to 
NCI by HIV serostatus have not been examined. Thus, this project aimed to 1) determine profiles 
of NCI among PLWH and HIV-uninfected older adults using LCA and 2) compare the effect of 
HIV-infection on the relationship between metabolic syndrome risk factors and profiles of NCI. 
We hypothesized that LCA would identify subgroups of PLWH and HIV-uninfected individuals 
that differ in profiles of NCI and that metabolic risk factors would have greater negative effects 
on cognition among PLWH. Specifically, we hypothesized that among PLWH, metabolic risk 
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factors would be associated with higher odds of classification in subgroups characterized by 
more extensive NCI.  
 
METHODS 
 
Participants  
 Data from 266 participants were selected from two HNRP-based studies of HIV and 
aging (Successfully Aging Seniors with HIV and Multi-Dimensional Successful Aging Among 
HIV-Infected Adults) at the University of California, San Diego. To enroll in these studies, 
participants had to be English-speaking and possessing the capacity to provide informed consent; 
an additional inclusion criterion for our analyses was age 50 years or older. Candidates were 
excluded if they had a history of conditions that might confound analyses, such as head injury 
with loss of consciousness for longer than 30 minutes, neurological disease with neurological or 
neuropsychiatric sequelae (e.g., stroke and seizure disorders), psychotic disorder, non-HIV 
degenerative brain diseases (e.g., diagnosis of dementia due to a condition other than HIV), or a 
severe learning disability (e.g., Wide Range Achievement Test Reading score <70).  
 
Measures  
 
Neurocognitive Functioning 
 Participants completed a comprehensive neurocognitive test battery covering seven 
ability domains (verbal fluency, executive functioning, speed of information processing, verbal 
and visual learning, verbal and visual delayed recall/memory, working memory, and motor 
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skills) (24). Following established procedures, Domain Deficit Scores (DDS) were computed 
from conversions of T-scores, demographically-corrected for the effects of age, education, sex 
and ethnicity (1, 25). Previous studies have shown a balance of sensitivity and specificity in 
identifying NCI using DDS cutoffs of > 0.5 (25); thus, participants were classified with NCI vs. 
no NCI in each of the seven domains using this DDS threshold. Additionally, deficit scores were 
averaged across all tests in the battery to create a Global Deficit Score (GDS) for each individual 
which was similarly dichotomized into ratings of impairment (GDS≥ 0.5) vs. no impairment 
(GDS < 0.5) (25, 26).  
 
Metabolic Comorbidities  
 Metabolic risk factors (i.e., dyslipidemia (elevated triglycerides and/or low HDL), central 
obesity (i.e., large waist circumference), diabetes, and hypertension) were determined from a 
combination of self-report (e.g., history of diabetes and/or hypertension) and objective laboratory 
(i.e., phlebotomy and anthropomorphic) assessments. Metabolic risk factors examined were 
consistent with the National Cholesterol Education Program Adult Treatment Panel III (NCEP 
ATP III) criteria for metabolic risk (27, 28). The NCEP ATP III panel defines metabolic risk as 
1) large waist circumference (> 102 cm [40 in] for men, 88 cm [35 in] for women), 2) elevated 
triglycerides (≥150 mg/dl) or prescription, 3) low HDL cholesterol (40 mg/dl in men, 50 
mg/dl in women) or prescription, 4) hypertension (>130mmHg systolic or >85 mmHg diastolic) 
or prescription, and 5) elevated fasting glucose (≥100 mg/dl) or prescription. Thus, if participants 
reported receiving a prior medical diagnosis, reported prescription of drug treatment for a 
condition, or if they had laboratory measurements for any of the conditions at or above NCEP 
ATP III thresholds, they were considered positive for that metabolic risk factor. Finally, to obtain 
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a diagnosis of MetS, indicators of MetS were summed into a composite variable, which ranged 
from 0 to 5, and an NCEP ATP III diagnosis of MetS applied if they had 3 or more of the factors.   
 
Alternative Measure of Cognitive Functioning 
 In addition to completing the standard neuropsychological battery, participants were also 
assessed using the Montreal Cognitive Assessment (MoCA), a well-validated neurocognitive 
screener for clinical geriatric populations (29).  
 
Potential Covariates 
 In addition to demographics, the following variables that have previously been associated 
with neurocognitive performance or MetS were considered as potential covariates affecting 
latent classification: 
 
Premorbid Functioning  
 All participants completed the reading subtest of the Wide Range Achievement Test-IV 
(WRAT-IV-Reading) (30). Single-word reading tests, such as the WRAT-IV, are common 
performance-based tools for estimating premorbid verbal IQ and the WRAT-IV has shown 
strong test-retest reliability as a measure of premorbid functioning (31, 32) 
 
Psychiatric, Behavioral, and Medical Conditions  
 The presence/absence of lifetime mood (e.g., major depressive disorder) and substance 
use disorders (e.g., alcohol use disorder) were evaluated with the Composite International 
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Diagnostic Interview (CIDI v.2.1), using diagnostic criteria based on the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (33).  
 
Hepatitis C and Tobacco Smoking 
Hepatitis-C (HCV) infection was diagnosed by enzyme-linked immunosorbent assay and 
lifetime smoking was obtained by participant self-report of tobacco smoking. 
 
HIV Disease and Treatment Characteristics.  
For PLWH, disease and treatment characteristics were collected by participant self-report 
and laboratory assessment. In particular, PLWH provided information about their estimated 
duration of HIV infection, length on current and previous ART regimens, and nadir CD4+ T-cell 
counts. Blood was also collected and clinical assays (e.g., complete blood count) performed by a 
Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory at the UCSD 
Medical Center. Current CD4+ T-cell count was measured by flow cytometry and HIV RNA 
levels in blood were measured by reverse transcriptase-polymerase chain reaction with a lower 
limit of quantitation (LLQ) at 50 viral copies/mL.  
 
Data Analysis 
 LCA was used to estimate the number of classes that best-captured similar patterns of 
DDS across the seven domains of neurocognitive performance. To determine the number of 
categorical latent classes underlying the observed patterns, several models with increasing 
numbers of latent classes were estimated. The best-fitting model was selected based on four 
indices: the Bayesian Information Criteria (BIC), Akaike Information Criteria (AIC), entropy, 
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and the bootstrapped likelihood ratio test (BLRT). For each model with k number of classes, the 
best log-likelihood was replicated in order to avoid convergence at a local maximum. 
Additionally, in log-likelihood ratio tests to examine model fit, the log-likelihood for the null 
model with k-1 classes was verified as being equal to the best log-likelihood value of the 
previously-tested model with one fewer class (34).  
 Once the optimum number of classes was identified, the final LCA model was adjusted 
for relevant covariates (i.e., any of the previously-described potential covariates that were 
correlated with latent classes at p< 0.10). Convergent validity of these covariate-adjusted classes 
was examined by comparisons of the means of scores on the MoCA across each of the identified 
latent classes using Wald 2–tests; corrections for Type I errors in multiple comparisons were 
made using the Benjamini-Hochberg procedure (35). The extent to which HIV infection 
moderated the association between metabolic disease characteristics and group membership in 
the identified latent classes was determined using multinomial regression.  
In all regressions and Wald tests, a “3-step” approach, in which class membership was 
assigned using observed DDS categorizations and relevant covariates prior to the inclusion in the 
model of outcome or predictors variables was used in order to prevent these auxiliary factors 
from altering the structure of latent classes and influencing final class membership (36, 37). All 
LCA analyses were conducted using Mplus version 7.4 using robust maximum likelihood 
estimation (MLR) that is robust to missing data and non-normal distributions of outcomes (38). 
 
RESULTS 
 
Prevalence of demographic and metabolic risk factors  
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 By the combined self-report and/or NCEP ATP III criteria, 162 (65.9%) participants had 
hypertension, 91 (37%) had central obesity, 173 (70.3%) had dyslipidemia, 42 (17.1%) had 
diabetes, and 93 (37.8%) had MetS. Of these, 46.3% of participants who were categorized as 
hypertensive reported prescription of antihypertensive medication, 69.0% of those categorized as 
having diabetes reported prescription of diabetes medication, and 48.6% of those with 
dyslipidemia were on lipid-lowering medication. With regards to demographics, participants 
were on average 57.96 years old (SD= 6.10 years), with 14.43 years of education (SD= 2.55 
years), and were predominantly non-Hispanic white (72.4%) and male (79.3%). Further detailed 
descriptive statistics of the sample, including summaries of study variables are presented in 
Table 1.  
 
Identification of Number of Latent Classes  
 Table 2 reports numbers of individuals assigned to latent classes and the indices of fit for 
LCA models that were tested separately among PLWH and HIV-uninfected participants. 
Through comparisons of indices of fit of LCA models with increasing number of classes, which 
ranged from 1 to 4, a 3-class model was found to best fit the observed DDS profiles in both the 
PLWH (BIC= 1057.50, Entropy= 0.91, and BLRT= 56.67, p< 0.001) and HIV-uninfected 
samples (BIC= 656.40, Entropy= 0.92, and BLRT= 20.84, p< 0.001). Panel A of Figure 1 
depicts the DDS profiles of the 3 classes among PLWH while Panel B depicts the profiles  
among HIV-uninfected individuals. As can be observed from the pattern of DDS categories 
across domains, the three classes in both the PLWH and HIV-uninfected samples can generally 
be described as Class 1Multidomain NCI (high probability of impairment across multiple domains), 
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Class 2Learning & Recall NCI (high probability of impairment in learning and recall), and Class 3NC 
Unimpaired (having low probability of NCI across all domains).  
A series of Wald chi-square tests (with adjustments for multiple comparisons) were 
carried out to examine differences in the estimated probabilities of impairment across all 
domains of cognitive performance within the three similar pairs of classes by HIV status. 
Comparing across all domains for Class 1Multidomain NCI, the estimated probability of impairment in 
speed of information processing was found to be significantly greater among PLWH than among 
HIV-uninfected individuals (Wald 2(1)= 155.14, adjusted p< 0.001). Among individuals 
classified as Class 2Learning & Recall NCI, verbal learning and working memory were more likely to be 
impaired among PLWH (Wald 2(1)= 155.11, p< 0.001 and Wald 2(1)= 164.72, p< 0.001, 
respectively). Additionally, despite the overall low probabilities of impairment, among 
individuals in Class 3NC Unimpaired, delayed recall was more likely to be impaired among PLWH 
(Wald 2(1)= 137.59, p< 0.001).  
As the number of latent classes and the overall pattern of impairment were similar for 
PLWH and HIV-uninfected individuals, both samples were combined and a new best-fitting 
LCA model that accounted for HIV (through the regression of class on HIV-serostatus) was 
estimated. Consistent with previous results, a 3-class model in the combined sample (with HIV 
serostatus as a covariate) was found to best describe the DDS categories across the seven 
neurocognitive domains (BIC= 1714.99, Entropy= 0.90, and BLRT= 83.78, p< 0.001).  
Multivariable regression analyses identified other potential covariates for inclusion as 
variables affecting class formation. Because only WRAT-IV reading level was associated with 
class membership in the HIV-adjusted LCA (p< 0.10), WRAT-IV was subsequently included as 
a covariate affecting class formation. Table 3 reports fit indices of the series of LCAs on the 
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combined sample for models that adjusted for HIV infection only and for the final 3-class LCA 
model that adjusted for HIV infection as well as WRAT-IV (BIC= 1714.08, Entropy= 0.92, and 
BLRT= 86.60, p< 0.001).  
Panel C of Figure 1 depicts the profiles of NCI of the final model (HIV serostatus- and 
WRAT-IV-adjusted) estimated on the combined sample. The interpretation of latent classes 
remained that of an impaired class across multiple domains (Class 1Multidomain NCI; NTotal= 39, 
NPLWH= 31, NHIV-uninfected= 8), an impaired class in learning and recall (Class 2Learning & Recall NCI; 
NTotal= 83, NPLWH= 32, NHIV-uninfected= 51), and an NC unimpaired class (Class 3NC Unimpaired; 
NTotal= 124, NPLWH= 62, NHIV-uninfected= 62). Examinations of the frequencies of global 
neurocognitive impairment (GDS≥ 0.5) across the three latent classes revealed that all 
participants in Class 1Multidomain NCI and 60.2% of participants in Class 2Learning & Recall NCI were also 
categorized as globally neuropsychologically-impaired. Despite low overall estimated 
probabilities of impairment among individuals in Class 3NC Unimpaired, 5.6% of participants in Class 
3NC Unimpaired were also classified as impaired based on GDS. 
 
Convergent validity of Latent Classes 
 Convergent validity of classification was examined by comparison of MoCA scores 
across the latent classes. Individuals in Class 3NC Unimpaired had the highest MoCA scores (Mean= 
26.32, SE= 0.26), followed by those in Class 2Learning & Recall NCI (Mean= 24.18, SE= 0.32), and 
finally by individuals in Class 1Multidomain NCI (Mean= 22.60, SE= 0.80). The omnibus 2-test was 
statistically significant (2(3)= 36.75, p< 0.001) and, relative to those in Class 3NC Unimpaired, 
individuals in Class 2Learning & Recall NCI and in Class 1Multidomain NCI had significantly lower scores 
on the MoCA (2(1)= 25.27, adjusted p= 0.001 and 2(1)= 18.63, adjusted p= 0.001, 
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respectively). MoCA scores between individuals in Class 1Multidomain NCI and in Class 2Learning & 
Recall NCI differed only with marginal significance, (2(1)= 3.19, adjusted p= 0.074).  
 
Predictors of Classification  
 Table 4 reports results of the multinomial regression of latent classes on metabolic risk 
factors. In all analyses, the interaction between metabolic risk and HIV serostatus was included 
in order to examine the differential effects by HIV serostatus. When an interaction was not 
significant, that term was discarded in order to interpret the main effects. PLWH with central 
obesity (OR= 2.80, p=.035), dyslipidemia (OR= 3.68, p=.029), and hypertension (OR= 3.79, p= 
0.019) had greater odds of classification in Class1Multidomain NCI, relative to Class 3NC Unimpaired. 
PLWH with MetS had marginally greater odds of classification in Class1Multidomain NCI, relative to 
Class 3NC Unimpaired (OR= 5.80, p= 0.078). Although the interaction of HIV serostatus and diabetes 
was not significant, diabetes was associated with greater odds of classification in Class1Multidomain 
NCI, relative to Class 3NC Unimpaired (OR= 2.86, p= 0.017). No significant differences by HIV 
serostatus were observed in the likelihood of classification as Class 2Learning & Recall NCI versus Class 
3NC Unimpaired. Furthermore, there were no significant predictors of classification in Class 2Learning & 
Recall NCI among the metabolic risk factors. 
 
Post-hoc analyses 
Additional post-hoc analyses examining the effect of HIV disease characteristics on 
classification were carried out to further examine the HIV effects. No significant relationships in 
the regression of the latent classes on nadir CD4, current CD4 count, duration of HIV infection, 
detectability of HIV viral proteins above the LLQ of 50 copies/mL, or duration on ART were 
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found. However, higher nadir CD4 was negatively associated with diagnosis of dyslipidemia (= 
-0.18, p= 0.035) while longer duration on cART was associated with MetS (= 0.20, p= 0.019) 
and diabetes (= 0.30, p< 0.001),  
 
DISCUSSION 
Multiple studies examining NCI have observed an association between aging, metabolic 
risk factors, and HIV infection; however, relationships between specific profiles of NCI, 
metabolic risk factors, and HIV serostatus have not been explored. Thus, in a sample of older 
adults, we aimed to characterize profiles of NCI and to examine HIV serostatus as a moderator 
of the link between metabolic risk factors and profiles of impairment. 
We utilized LCA, a person-centered statistical classification technique of examining 
heterogeneity to identify distinct neuropsychological profiles of NCI among PLWH and HIV-
uninfected individuals. In our sample of older adults, approximately 8% of HIV-uninfected and 
22% of PLWH were classified as having overall high rates of impairment across all 
neurocognitive domains (Class 1Multidomain NCI), while 31% of HIV-uninfected and 35% of PLWH 
were classified as primarily impaired in learning and delayed recall (Class 2Learning & Recall NCI). A 
sizeable proportion of individuals in both groups (~ 61% of HIV-uninfected individuals and 43% 
of PLWH) were classified as neurocognitively intact (Class 3NC Unimpaired). Thus, PLWH were 
more heavily represented in the latent class characterized by appreciable NCI. The convergent 
validity of these classes was supported by findings of the degree of NCI within latent classes 
tracking with worsening neurocognitive performance on an independent measure of 
neurocognitive performance, the MoCA. In particular, individuals in Class 1Multidomain NCI and 
Class 2Learning & Recall NCI had average MoCA scores below the clinical cutoff of 26/30 that 
Metabolic Risk and Neurocognitive Impairment 
17 
 
corresponds to a preliminary diagnosis of mild NCI (29). Furthermore, the average MoCA scores 
of individuals in Class 1Multidomain NCI was lower than that of individuals in Class 2Learning & Recall 
NCI, suggesting that the widespread pattern of NCI observed in Class 1Multidomain NCI paralleled a 
greater degree of clinical impairment than in the other two classes.  
Previous studies have described the domain-specific patterns of NCI in PLWH as 
“spotty” and this study confirmed findings of variable patterns of NCI among PLWH (1). We 
found that three distinct patterns of NCI predominate among PLWH and that they are similar to 
profiles of NCI among HIV-uninfected individuals; thus, NCI phenotypes in HIV-infection may 
not be unique and may reflect shared or similar pathogenic mechanisms. Although the patterns of 
impairment and interpretations of classes were similar across PLWH and HIV-uninfected 
samples, some domains within similar pairs of classes appeared to be more vulnerable to 
impairment among PLWH. In particular, in Class 1Multidomain NCI, impaired speed of information 
processing tended to be more prevalent among PLWH, while learning and working memory 
were more greatly affected in Class 2Learning & Recall NCI, and delayed recall appeared more affected 
in Class 3NC Unimpaired. This greater impairment among PLWH in speed of information processing, 
learning, recall, and working memory is consistent with preferential involvement of fronto-
striatal brain regions (39).  
Previous work has also used clustering approaches to identify profiles of neurocognitive 
performance among PLWH and HIV-uninfected individuals and identified varying numbers of 
classes (21, 40-44). Some of the differences in these studies may be a function of the clustering 
method (e.g., cluster analysis vs. LCA), sample size, the nature of indicators of 
neuropsychological performance, and populations at risk for NCI. Thus, the number of classes 
obtained in this study may differ from those previously identified in other studies. However, 
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despite variability in the number of estimated classes underlying neurocognitive performance, 
clusters of NC performance similar to the three classes obtained in this study have previously 
been observed. Indeed, other studies have found evidence of classes of individuals with few 
deficits, classes with some exhibiting global NCI, and others with NCI that is primarily amnestic, 
suggesting the ubiquity of these patterns of NCI across different samples (21, 41-43).   
When predictors of classification were examined, diabetes was found to be associated 
with multidomain NCI, regardless of HIV status. Additionally, PLWH classified as having 
widespread multidomain NCI were more likely to have hypertension, dyslipidemia, and central 
obesity. These findings, that HIV infection can amplify the detrimental effects of metabolic risk 
factors on cognition, are consistent with those of other studies that have similarly noted the 
potentiation of neurocognitive insults in the context of HIV infection (14, 17). Given this, there 
may be a need for interventions that focus on supporting the cardio-metabolic well-being of 
PLWH that may limit or reverse declines in cognition. Additionally, strategies to further promote 
neurocognitive well-being may need to be applied. A good example of this may be of the 
provision of “cognitive prescriptions” by medical professionals to their patients (i.e., advocating 
physical activity and engagement in cognitively-demanding activities, as well as promoting 
adequate nutrition and sleep) in order to maintain or improve cognitive health (45). Such 
encouragement of healthy behaviors would stand to benefit all individuals and PLWH in 
particular. Furthermore, given documented low rates of diagnosis of metabolic conditions and 
prescription of medications to manage them within the general population, facilitating increased 
access and engagement in medical care will also have significant implications for individual 
well-being and public health (46). 
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Our study had several important limitations. First, following the inclusion of HIV 
serostatus as a covariate in our classification, only a small number of HIV-uninfected individuals 
were classified in Class 1Multidomain NCI. Thus, comparisons of the effects of MetS components by 
HIV status are limited by the small numbers of HIV-uninfected participants in this class.  
Furthermore, a sizeable proportion of both PLWH and HIV-seronegative individuals were 
identified as significantly impaired in learning and recall and found to have measurable deficits 
on the MoCA. However, a limitation of this work is that our findings do not speak to the 
identification of predictors of learning and recall impairment. Future work should consider 
alternative sets of risk factors to identify vulnerabilities for this form of NCI.  
Second, we examined the convergent validity of latent classification against the MoCA 
and found evidence to suggest that differences in the degree of severity of NCI implied by the 
three latent classes corresponded to differences in cognitive dysfunction captured by this 
standardized external measure. However, as the MoCA is a brief screener, it is less 
comprehensive and almost certainly less sensitive to HAND and other forms of NCI than the 
standard neuropsychological test battery that was utilized in LCA analyses. Given this, more 
comprehensive measures should be considered in future work to assess construct validity.  
Furthermore, our analyses are cross-sectional; thus, we are unable to determine whether 
these latent classes have implications for the future course of neurocognitive health. Longitudinal 
studies are needed to examine if metabolic risk factors predict future cognitive impairment, 
including the development of dementia, and whether they may speak to the disentanglement of 
HAND from Alzheimer’s among PLWH (47). Future studies should also examine the effects of 
sex and racial /ethnic differences on patterns of performance on neuropsychological tests among 
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older individuals and combine these studies with neuroimaging and the assessment of 
biomarkers. 
 In summary, this study utilized LCA to model heterogeneity in the neurocognitive 
performance of older adults living with and without HIV infection and related profiles of NCI to 
metabolic risk factors. PLWH with metabolic risk factors were at increased risk of multi-domain 
NCI and early intervention to reduce these metabolic risk factors may improve the 
neurocognitive outcomes of PLWH. However, additional longitudinal observational studies, 
coupled with imaging and biomarkers, could help to inform and target interventional approaches. 
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TABLE 1. Characteristics of Study Participants by HIV Serostatus 
 
PLWH 
(n = 144) 
HIV-uninfected 
(n = 102) p-value 
Demographic Characteristics 
Age; mean (SD) 57.85 (6.17) 58.10 (6.03) .76 
Years of education; mean (SD) 14.36 (2.62) 14.53 (2.46) .61 
WRAT 103.08 (14.71) 106.35 (14.5) .085 
MoCA 24.66 (3.43) 25.67 (2.96) .015 
Male, n (%) 129 (89.6%) 66 (64.7%) <.001 
Race/Ethnicity   .54 
     Non-Hispanic white, n (%) 105 (72.9%) 73 (71.6%) -- 
     Black, n (%) 18 (12.5%) 17 (16.7%) -- 
     Hispanic, n (%) 12 (8.3%) 9 (8.8%) -- 
     Other, n (%) 9 (6.3%) 3 (2.9%) -- 
Ever Smoked, n (%) 62 (43.1%) 27 (26.5%) .004 
Lifetime Substance Use Disorder, n (%)  72 (50.0%) 43 (42.2%) .24 
Lifetime Major Depression, n (%) 83 (57.6%) 25 (24.5%) <.001 
Hepatitis C virus-infected, n (%) 25 (17.4%) 8 (7.8%) .024 
Metabolic Conditions    
Diabetes, n (%) 31 (21.5%) 11 (10.8%) .020 
Hypertension, n (%) 98 (68.1%) 64 (62.7%) .35 
Dyslipidemia, n (%) 115 (79.9%) 58 (56.9%) <.001 
Central Obesity, n (%) 40 (27.8%) 51 (50.0%) <.001 
Metabolic Syndrome, n (%) 59 (40.1%) 34 (33.3%) .22 
HIV Disease Characteristics 
Undetectable viral load, n (%) 130 (90.3%) - - 
Estimated duration of HIV (years), median [IQR]  19.2 [13.1, 25.8] - - 
On cART, n (%) 138 (97.2%) - - 
Months on current cART regimen, median [IQR]  37.6 [11.1, 72.3] - - 
Months on any cART regimen, median [IQR]  141.3 [77.0, 207.5] - - 
Nadir CD4+ T-cells, median [IQR] 145 [39, 300] - - 
Current CD4+ T-cells, median [IQR] 602 [414, 785] - - 
Note: IQR = interquartile range. Nadir CD4 count is the lowest of self-reported or laboratory-
obtained value.   
Table Click here to download Table epasipanodya_tables.docx 
TABLE 2. Results of LCAs Among PLWH And HIV-uninfected Adults  
 Number 
of classes 
Log-
likelihood (# 
of free 
parameters) 
AIC BIC Entropy 
Number (%) 
per class 
BLRT 
PLWH      
1 -631.61 (7) 1277.22 1275.86 1.00 144 (100%) N/A 
2 -536.321 (15) 1102.65 1099.73 0.83 47 (32.6%)  
97 (67.4%) 
190.57,  
p < 0.001 
3 -507.989 (23) 1061.98 1057.53 0.91 30 (20.8%)  
52 (36.1%)  
62 (43.1%) 
56.67, 
 p < 0.001 
4 -500.37 (31) 1062.75 1056.72 0.92 5 (3.5%)  
28 (19.4%)  
50 (34.7%)  
61 (42.4%) 
15.23,  
p = 0.29 
HIV-uninfected      
1 -364.22 (7) 742.43 738.69 1.00 120 (100%) N/A                           
2 -321.76 (15)  673.16 665.51 0.83 37 (36.3%)  
65 (63.7%) 
84.91, 
 p < 0.001 
3 -311.34 (23) 668.67 656.40 0.92 15 (14.7%)  
27 (26.5%) 
60 (58.8%) 
20.84,  
p < 0.001 
4 -303.24 (31) 668.48 651.94 0.91 6 (5.8%)  
9 (8.8%) 
32 (32.4%) 
55 (53.9%) 
16.19,  
p = 0.17 
Note: AIC = Akaike Information Criterion, BIC = Bayesian Information Criterion, LMR-LT = Lo Mendell Rubin Likelihood Ratio 
Test, BLRT = Bootstrapped Likelihood Ratio Test  
TABLE 3. Results for LCAs in the Combined Sample (PLWH and HIV-uninfected Individuals), Adjusted for Relevant Covariates 
  
Log-likelihood 
(# of free 
parameters) 
AIC BIC Entropy Number (%) per class BLRT 
HIV-adjusted       
1 -1013.80 (7) 2041.59 2043.94 1.00 246 (100%) N/A 
2 -870.19 (16) 1772.39 1777.75 0.79 82 (33.3%) 
164 (66.7%) 
287.20, 
p < 0.001 
3 -828.30 (25) 1706.61 1714.99 0.90 39 (15.9%) 
74 (30.0%) 
133 (54.1%) 
83.78, 
p < 0.001 
4-  -823.26 (34) 1714.52 1725.93 0.87 31 (12.6%) 
36 (14.6%) 
53 (21.5%) 
126 (51.2%) 
10.09, 
p > 0.99 
HIV- and WRAT-adjusted      
3 -825.51 (27) 1705.03 1714.08 0.92 39 (15.9%) 
83 (33.7%) 
124 (50.4%) 
86.60, 
p <.001 
Note: AIC = Akaike Information Criterion, BIC = Bayesian Information Criterion, LMR-LT = Lo Mendell Rubin Likelihood Ratio 
Test, BLRT = Bootstrapped Likelihood Ratio Test  
TABLE 4. Regression Estimates Obtained From Multinomial Models Examining Predictors of Classification 
 
Outcome: Classification in Class 1Multidomain NCI Outcome: Classification in Class 2Learning & Recall NCI 
Predictor Estimate SE Odds 
Ratio 
p -
value 
Predictor Estimate SE Odds 
Ratio 
p -
value 
Central Obesity -0.45 0.41 0.64 0.27 Central Obesity -1.12 0.68 0.33 0.10 
Central Obesity*HIV Status 1.03 0.49 2.80 0.035 Central Obesity*HIV Status 1.21 0.81 3.34 0.14 
WRAT -0.04       0.02      0.97 0.093 WRAT -0.01       0.02      0.99 0.55 
HIV Status 1.41       0.51       4.11 0.005 HIV Status 0.42       0.32       1.53 0.18 
Dyslipidemia -0.79 0.67 0.46 0.24 Dyslipidemia -0.64 0.42 0.53 0.12 
Dyslipidemia*HIV Status 1.30 0.60 3.68 0.029 Dyslipidemia*HIV Status 0.56 0.39 3.02 0.15 
WRAT -0.04      0.02      0.97 0.093 WRAT -0.01       0.02      0.99 0.55 
HIV Status 1.41       0.51       4.11 0.005 HIV Status 0.42       0.32      1.53 0.18 
Hypertension -0.35 0.63 0.71 0.58 Hypertension -0.09 0.39 0.91 0.81 
Hypertension*HIV Status 1.33 0.57 3.79 0.019 Hypertension*HIV Status 0.38 0.38 1.46 0.32 
WRAT -0.04       0.02      0.97 0.093 WRAT -0.01       0.02      0.99 0.55 
HIV Status 1.41       0.51       4.11 0.005 HIV Status 0.42       0.32       1.53 0.18 
Diabetes 0.16 0.87 1.17 0.86 Diabetes -1.04 0.94 0.35 0.27 
Diabetes*HIV Status 1.19 0.94 3.28 0.21 Diabetes*HIV Status 0.89 1.06 2.43 0.40 
WRAT -0.04       0.02      0.97 0.093 WRAT -0.01       0.02      0.99 0.55 
HIV Status 1.41     0.51       4.11 0.005 HIV Status 0.42       0.32      1.53 0.18 
MetS -1.08 0.96 0.34 0.26 MetS -0.37 0.47 0.69 0.42 
MetS*HIV Status 1.76 1.00 5.80 0.078 MetS*HIV Status 0.59 0.54 1.81 0.27 
WRAT -0.04       0.02      0.97 0.093 WRAT -0.01       0.02      0.99 0.55 
HIV Status 1.41       0.51       4.11 0.005 HIV Status 0.42       0.32      1.53 0.18 
Note: Provided estimates are relative to classification in Class 3NC Normal.
 
 
 
FIGURE 1. Panels depicting the 3-class LCAs of Cognitive Impairment Among PLWH, HIV-uninfected participants, and in a 
Combined Sample  
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